Pearson acquires therapeutic technology for individuals with ADHD
Acquisition of Revibe Technologies software assets enables Pearson to enhance clinician’s capabilities and the lives of individuals with ADHD
London, 31 Oct. 2024 – Pearson (FTSE: PSON.L), the world’s lifelong learning company, today announced it has acquired the assets of Revibe Technologies, a digital therapeutics company that has developed technology to treat children with attention- deficit/hyperactivity disorder (ADHD).
Revibe is a developer of proprietary software and machine learning models that will utilize features and data from third-party smartwatch devices to treat ADHD. The technology will enable clinicians in healthcare and educational settings to gain valuable insights about children’s behaviors and the correlation to environmental factors that impact children with ADHD.
Revibe’s software uses third-party smartwatch devices to provide vibration and text reminders to help improve children’s focus and attention by bolstering their ability to self-regulate. Revibe’s technology also passively and securely collects data, which are analyzed by its assessment platform to provide parents, researchers, and clinicians with insights for decision-making, monitoring, and personalized therapy.
Revibe’s software and intellectual property will be incorporated into Pearson’s portfolio of tools and resources that are helping to modernize clinical assessment and improve outcomes for people with ADHD.
“An estimated seven million children are living with ADHD in the US alone, and as diagnoses rise, it’s critical that we have the right capabilities to identify and treat the condition. Bringing Revibe’s innovative software into our portfolio will strengthen our ability to deliver lifelong learning for all with tools and resources that improve clinician capabilities and enhance the lives of children with ADHD,” said Clay Richey, Vice President of Global Portfolio Management and Delivery for Pearson Clinical Assessment.
“I’m proud of the work we’ve done at Revibe to enable greater insight and intervention for children and families impacted by focus and attention challenges. Incorporating Revibe and our smartwatch-enabled data collection capabilities into Pearson’s broader assessment offerings will greatly accelerate our ability to bring these innovations to a wider audience.” said Rich Brancaccio, CEO & Founder, Revibe Technologies.
If left untreated, ADHD can cause serious issues in relationships, school, and work. ADHD symptoms can present differently in each person, which means diagnoses need to be approached from many angles. Pearson provides tools, assessments, and resources to help identify ADHD, along with learning materials and interventions designed to help manage ADHD in educational settings.
Pearson is a longstanding leader in clinical assessment, catering to the requirements of psychologists, educators, speech pathologists, and other professionals in both education and healthcare settings.
About Pearson
At Pearson, our purpose is simple: to help people realize the life they imagine through learning. We believe that every learning opportunity is a chance for a personal breakthrough. That's why our c. 18,000 Pearson employees are committed to creating vibrant and enriching learning experiences designed for real-life impact. We are the world's lifelong learning company, serving customers in nearly 200 countries with digital content, assessments, qualifications, and data. For us, learning isn't just what we do. It's who we are. Visit us at pearsonplc.com.
About Pearson Clinical Assessment
With 80 years of expertise, Pearson's Clinical Assessment group provides tools and services to clinical professionals globally from 13 international offices. Serving psychologists, occupational therapists, speech-language pathologists, and others, our renowned portfolio features Wechsler, Kaufman, MMPI, BASC, BECK, CELF, and PLS brands. Pearson's clinical assessment contributions include those for cognitive, ability, memory, neuropsychology, behavior, personality, psychopathology, achievement, and speech/language.